Biorhythm-mimicking growth hormone patch.
Summary
A multistage-release microneedle patch that mimics nocturnal growth hormone pulsatility outperformed daily subcutaneous injections in rodent models, increasing bone length by ~10 mm (healthy rats) and ~5 mm (GH knockout mice), and improving bone quality. The chronopharmacology-aligned profile boosted IGF-1 and GH bioavailability.
Key Findings
- Engineered a microneedle patch with burst and delayed-release modules to mimic nocturnal GH pulsatility.
- Enhanced longitudinal bone growth (~10 mm in healthy rats; ~5 mm in GH knockout mice) and improved bone quality versus daily subcutaneous GH.
- Increased IGF-1 secretion and GH bioavailability with biorhythm-mimicking release.
Clinical Implications
If translated to humans, nocturnal, pulsatile-mimicking GH delivery could enhance efficacy, adherence, and bone outcomes versus daily injections; clinical studies must assess pharmacokinetics, safety, immunogenicity, and real-world usability.
Why It Matters
Introduces a programmable, physiology-mimicking hormone delivery platform with superior preclinical efficacy, potentially transforming pediatric and adult GH replacement by aligning with natural secretion rhythms.
Limitations
- Preclinical animal study; no human pharmacokinetic or safety data
- Manufacturing scalability and long-term device tolerability remain untested
Future Directions
Conduct first-in-human studies to assess pharmacokinetics, safety, and efficacy versus standard GH injections, and evaluate adherence, patient experience, and cost-effectiveness.
Study Information
- Study Type
- Case series
- Research Domain
- Treatment
- Evidence Level
- V - Preclinical experimental evidence in animal models; no human clinical data.
- Study Design
- OTHER